Semaglutide
Also known as: Semaglutide (GLP-1 agonist)
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.
Who's worth your money for Semaglutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (96) of 6 scored sellers
$60.00 · 20mg · 99.2% purity
Best value
Lowest $/mg among scored sellers
$10.00 · 10mg
Most tested
11 independent COAs on file
$90.00 · 10mg · 99.9% purity
Average price
$6.70/mg
Sellers
23
45-day trend
+4.5%
20 of 23 sellers have a current price· 14 stale hidden
Top Merit pick
🇺🇸 Prime Peptides96✓ verified at source · just now
$3.00/mg -55.2% vs avg$60.00
20mg
- 🇺🇸 Polaris Peptides88
✓ verified at source · just now
$9.00/mg +34.4% vs avg$90.00
10mg
- 🇨🇳 Reta Peptide83
✓ verified at source · just now
$6.50/mg -3% vs avg$65.00
10mg
- 🇺🇸 Bulk Peptides50
✓ verified at source · just now
$16.00/mg +138.8% vs avg$160
10mg
- 🇭🇰 Hkuppeptide48
✓ verified at source · just now
$1.00/mg -85.1% vs avg$10.00
10mg
no purity - 🇭🇰 zztai Peptide Ltd42
✓ verified at source · 2d ago
$3.87/mg -42.3% vs avg$116
30mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Semaglutide
Get one email when the market actually moves — no newsletter, no noise.
About Semaglutide
CAS
910463-68-2
Molecular formula
C187H291N45O59
Typical dose range
0.25–2.4 mg (250–2400 mcg) subcutaneous once weekly; typically titrated from 0.25 mg/week, increasing every 4 weeks
Half-life
~7 days
COAs for Semaglutide
196 third-party tests across 31 vendors. Each card links to the full report.
For
Semaglutide
by Ignite Peptides· batch SM20392
For
Semaglutide
by VoriLabs· batch SEMA_2608-A
For
Semaglutide
by Velora Biolabs· batch VBL-SM20-1
For
Semaglutide
by Peptide Plugs· batch 189-02-DK
For
Semaglutide
by VoriLabs· batch VoriLabs SEMA-2607-C
For
Semaglutide
by VoriLabs· batch VoriLabs SEMA-2607-B
For
Semaglutide
by EZ Peptides· batch EZP-1P1007112026-04
For
Semaglutide
by Synthesis Peptides· batch 1G10826
For
Semaglutide
by Hydro Research Peptides· batch HR-2026-7341
For
Semaglutide
by Longeva· batch B-2026-SEMA-5-001
For
Semaglutide
by Peptide Partners· batch SPL-4149
For
Semaglutide
by Peptide Plugs· batch 125-01-SM
For
Semaglutide
by Soma Peptides· batch SEV052657
For
Semaglutide
by Certified Peptides· batch 260518SG53
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by Blank Peptides· batch GS10-052026-4
For
Semaglutide
by Pepsgpt· batch P-2885342-P
For
Semaglutide
by Prime Peptides· batch 3022026SM
For
Semaglutide
by Prime Peptides· batch 3142026SM
For
Semaglutide
by Prime Peptides· batch 2242026SM
For
ION-1S
by Ion Peptide· batch ION1S20-04172026
For
Semaglutide
by Vertex Labs· batch SM0000038
For
Semaglutide
by OROS Research· batch OR-LPGLPS10-426-B3
23 citations indexed for Semaglutide
rct · Ongoing
Semaglutide for the Treatment of Cannabis Use Disorder
The goal of this pilot study is to learn about the effects of semaglutide on brain reactivity to cannabis-related cues in adults with cannabis use disorder. The main questions it aims to answer are: 1. Does semaglutide effect reactivity to cannabis-related cues? 2.
Study · 2026
Oral Semaglutide and the Kidney: Promise, Limitations, and the Road Ahead
Study · 2026
Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance
Purpose To evaluate how confounding by indication and notoriety bias shape the apparent semaglutide-panic attack signal in the FDA Adverse Event Reporting System (FAERS) and to interpret this signal using an evidence-triangulation framework integrating randomized and observational studies.
cohort · 2026
Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS
Background Semaglutide and tirzepatide are widely used for type 2 diabetes and obesity, but comparative post-marketing safety data remain limited.
Study · 2026
Semaglutide and Cardiovascular Death: a Systematic Review and Meta-Analysis Cardioprotective Efficacy of Semaglutide
Background Cardiovascular death (CVD) remains a leading cause of global mortality. Although semaglutide reduces major adverse cardiovascular events (MACE), the consistency and exact magnitude of its standalone effect on CVD across various patient phenotypes require comprehensive evaluation.
case-report · 2026
Starvation-associated high-anion gap metabolic acidosis following short-term oral semaglutide use: A case report
Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used for weight reduction beyond its approved indications. We report a case of starvation-associated euglycemic ketoacidosis in a previously healthy, nondiabetic young woman following short-term oral semaglutide use.